G
Günther G. Steger
Researcher at Medical University of Vienna
Publications - 243
Citations - 11875
Günther G. Steger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 41, co-authored 238 publications receiving 10859 citations. Previous affiliations of Günther G. Steger include University of Vienna.
Papers
More filters
Journal ArticleDOI
Brain metastasis-free survival in patients with HER2-positive metastatic breast cancer.
Anna Sophie Berghoff,Zsuzsanna Bago-Horvath,P. Dubsky,Margarethe Rudas,Ursula Pluschnig,Andrea Rottenfusser,Michael Gnant,Günther G. Steger,Christoph C. Zielinski,Rupert Bartsch +9 more
TL;DR: Trastuzumab-based therapy significantly prolongs BM free survival in HER2-positive pts with MBC, probably due to improved systemic disease control, and ER/HER2 co-positive disease appears to be a less aggressive subtype of HER1-positive breast cancer associated with longer BMFS.
Journal ArticleDOI
AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab
Alison Stopeck,Allan Lipton,M. Martin,J.J. Body,Alexander H.G. Paterson,Günther G. Steger,Katia Tonkin,R H de Boer,Yasuhiro Fujiwara,Denise A. Yardley,Jacek Jassem,Toshimi Takano,Philippe Solal-Celigny,Michelle Fan,Ada Braun +14 more
TL;DR: This OL extension treatment phase confirmed the safety profile of denosumab in patients with breast cancer with BMs receiving up to 5 years of monthly denosUMab therapy or switching to denOSumab after up to 3 years of ZA.
Journal ArticleDOI
Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
Robert M. Mader,C. Schrolnberger,Blanka Rizovski,Martin Brunner,Catharina Wenzel,Gottfried J. Locker,Hans-Georg Eichler,Manfred W. Mueller,Günther G. Steger +8 more
Adequacy of anticipatory anxiety in women receiving chemotherapy for breast cancer
TL;DR: Results indicate that trait anxiety and expectations of occurrence of side effects contribute to pre-treatment anxieties and patients should be informed as desired to avoid inappropriate and overwhelming anxiety.
Journal ArticleDOI
Active Her-2/neu signal transduction in breast cancer –relevance of a ligand-independent activation mechanism and impact on the efficacy of trastuzumab-based treatment
Gernot Hudelist,W. Koestler,Johannes Attems,Klaus Czerwenka,R. Mueller,M. Manavi,Günther G. Steger,Ernst Kubista,C. J. Zielinski,Christian F. Singer +9 more
TL;DR: These data strongly suggest that proteolytic cleavage of the ECD represents a biologically relevant ligand-independent mechanism of Her-2/neu activation in vivo and merits further investigation in larger prospective trials.